Serum FGF23 and VEGF-A Levels as Potential Biomarkers of Disease Severity in Retinopathy of Prematurity
DOI:
https://doi.org/10.31288/Ukr.j.ophthalmol.202644248Keywords:
retinopathy of prematurity, FGF23, VEGF-A, angiogenesis, lymphocyte activation biomarkers, preterm infantAbstract
Purpose. To evaluate the diagnostic and prognostic significance of serum FGF23 and VEGF-A levels in newborns with retinopathy of prematurity and to analyze their association with clinical characteristics of the disease.
Material and Methods. A prospective comparative study was conducted including 120 newborns: 42 preterm infants with retinopathy of prematurity, 40 preterm infants without signs of the disease, and 38 full-term newborns. Serum concentrations of FGF23 and VEGF-A were determined using enzyme-linked immunosorbent assay (ELISA). The relationship between biomarker levels and clinical parameters of ROP was assessed using Spearman’s rank correlation coefficient.
Results. Significantly higher serum levels of FGF23 (185±42 pg/mL) and VEGF-A (1.35±0.42 ng/mL) were detected in preterm infants with retinopathy of prematurity compared with both preterm infants without ROP and full-term newborns (p<0.05). FGF23 levels demonstrated a moderate positive correlation with disease stage (r=0.611; p<0.05), while VEGF-A levels also showed a statistically significant positive correlation (r=0,505; p<0.05). In addition, higher FGF23 concentrations were observed in patients who required treatment.
Conclusion. Serum FGF23 and VEGF-A levels were significantly elevated in preterm infants with ROP and showed positive correlations with disease severity. Higher FGF23 concentrations were also associated with the need for treatment, supporting its potential prognostic value. Combined assessment of FGF23 and VEGF-A may provide additional information for evaluating disease severity in preterm infants with ROP.
References
Marra KV, Chen JS, Nudleman E, Robbins SL. Review of Retinopathy of Prematurity Management in the Anti-VEGF Era: Evolving Global Paradigms, Persistent Challenges and Our AI-Assisted Future. Clin Exp Ophthalmol. 2025 Dec;53(9):1202-1217. https://doi.org/10.1111/ceo.14598
Hellgren G, Löfqvist C, Hård AL, Hansen-Pupp I, Gram M, Ley D, Smith LE, Hellström A. Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity. Pediatr Res. 2016 Jan;79(1-1):70-5. https://doi.org/10.1038/pr.2015.181
Huang D, Liu Z, Deng Y. Retinopathy of Prematurity (ROP): An Overview of Biomarkers in Various Samples for Prediction, Diagnosis, and Prognosis. Clin Ophthalmol. 2025 May 7;19:1515-1530. https://doi.org/10.2147/OPTH.S519292
Sjöbom U, Hellqvist T, Humayun J, Nilsson AK, Gyllensten H, Hellström A, Löfqvist C. Circulating VEGF-A Levels in Relation to Retinopathy of Prematurity and Treatment Effects: A Systematic Review and Meta-Analysis. Ophthalmol Sci. 2024 May 7;4(6):100548. https://doi.org/10.1016/j.xops.2024.100548
Goswami B, Goyal M, Beri S, Garg R, Saili A, Jain A. Role of Serum Levels of Vascular Endothelial Growth Factor and Its Receptor in Retinopathy of Prematurity. Iran J Pediatr. 2015 Aug;25(4):e2373. https://doi.org/10.5812/ijp.2373
Cheng Y, Zhu X, Linghu D, et al. Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity. Sci Rep. 2020 Aug;10:12695. https://doi.org/10.1038/s41598-020-69684-7
Yusupov AF, Karimova MKh, Usmanova YA. Relationship of Fibroblast Growth Factor 23 With Retinopathy of Prematurity Severity in Preterm Infants. Int J Med Sci Clin Res. 2025 Aug;5(8):12-15. https://doi.org/10.37547/ijmscr/Volume05Issue08-03
Kaur K, Mikes BA. Retinopathy of Prematurity. 2025 Jun 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
Kumawat D, Kandasamy S, Chandra P. Reactivation of retinopathy of prematurity after anti-VEGF treatment: a review. Br J Ophthalmol. 2026 Jan 22;110(2):117-124.https://doi.org/10.1136/bjo-2025-327597
Shah PK, Abiramalatha T, Quinn GE, Darlow BA, Marlow N, Fielder AR. Retinopathy of prematurity: Still more to do. Indian J Ophthalmol. 2025 Nov 1;73(11):1693-1694.https://doi.org/10.4103/IJO.IJO_669_25
Pieh C, Agostini H, Buschbeck C, Krüger M, Schulte-Mönting J, Zirrgiebel U, Drevs J, Lagrèze WA. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol. 2008 May;92(5):689-93. https://doi.org/10.1136/bjo.2007.128371
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Yusupov A. F., Usmanova Y. A., Karimova M. Kh., Djamalova S. A.
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
